Radiation Oncology Journal

  • 제31권4호
  • /
  • Pages.206-215
  • /
  • 2013
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Re-irradiation of unresectable recurrent head and neck cancer: using Helical Tomotherapy as image-guided intensity-modulated radiotherapy

  • Jeong, Songmi (Department of Radiation Oncology, The Catholic University of Korea College of Medicine) ;
  • Yoo, Eun Jung (Department of Radiation Oncology, The Catholic University of Korea College of Medicine) ;
  • Kim, Ji Yoon (Department of Radiation Oncology, The Catholic University of Korea College of Medicine) ;
  • Han, Chi Wha (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Kim, Ki Jun (Department of Diagnostic Radiology, The Catholic University of Korea College of Medicine) ;
  • Kay, Chul Seung (Department of Radiation Oncology, The Catholic University of Korea College of Medicine)
  • 투고 : 2013.09.17
  • 심사 : 2013.10.24
  • 발행 : 2013.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Re-irradiation (re-RT) is considered a treatment option for inoperable locoregionally recurrent head and neck cancer (HNC) after prior radiotherapy. We evaluated the efficacy and safety of re-RT using Helical Tomotherapy as image-guided intensity-modulated radiotherapy in recurrent HNC. Materials and Methods: Patients diagnosed with recurrent HNC and received re-RT were retrospectively reviewed. Primary endpoint was overall survival (OS) and secondary endpoints were locoregional control and toxicities. Results: The median follow-up period of total 9 patients was 18.7 months (range, 4.1 to 76 months) and that of 3 alive patients was 49 months (range, 47 to 76 months). Median dose of first radiotherapy and re-RT was 64.8 and 47.5 $Gy_{10}$. Median cumulative dose of the two courses of radiotherapy was 116.3 $Gy_{10}$ (range, 91.8 to 128.9 $Gy_{10}$) while the median interval between the two courses of radiation was 25 months (range, 4 to 137 months). The response rate after re-RT of the evaluated 8 patients was 75% (complete response, 4; partial response, 2). Median locoregional relapse-free survival after re-RT was 11.9 months (range, 3.4 to 75.1 months) and 5 patients eventually presented with treatment failure (in-field failure, 2; in- and out-field failure, 2; out-field failure, 1). Median OS of the 8 patients was 20.3 months (range, 4.1 to 75.1 months). One- and two-year OS rates were 62.5% and 50%, respectively. Grade 3 leucopenia developed in one patient as acute toxicity, and grade 2 osteonecrosis and trismus as chronic toxicity in another patient. Conclusion: Re-RT using Helical Tomotherapy for previously irradiated patients with unresectable locoregionally recurrent HNC may be a feasible treatment option with long-term survival and acceptable toxicities.

키워드

참고문헌

  1. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8. https://doi.org/10.1056/NEJMoa031317
  2. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933-40. https://doi.org/10.1016/S0140-6736(03)14361-9
  3. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52. https://doi.org/10.1056/NEJMoa032641
  4. Lefebvre JL, Rolland F, Tesselaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009;101:142-52. https://doi.org/10.1093/jnci/djn460
  5. Spector JG, Sessions DG, Haughey BH, et al. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope 2001;111:1079-87. https://doi.org/10.1097/00005537-200106000-00028
  6. Wong SJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol 2006;24:2653-8. https://doi.org/10.1200/JCO.2005.05.3850
  7. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin OncoI 1992;1O:257-63. https://doi.org/10.1200/JCO.1992.10.2.257
  8. Forastiere AA, Neuberg D, Taylor SG 4th, DeConti R, Adams G. Phase II evaluation of Taxol in advanced head and neck cancer: an Eastern Cooperative Oncology group trial. J Natl Cancer InstMonogr 1993;(15):181-4.
  9. Kasperts N, Slotman B, Leemans CR, Langendijk JA. A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol 2005;41:225-43. https://doi.org/10.1016/j.oraloncology.2004.07.006
  10. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008;30:281-8. https://doi.org/10.1002/hed.20697
  11. De Crevoisier R, Bourhis J, Domenge C. et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998;16:3556-62. https://doi.org/10.1200/JCO.1998.16.11.3556
  12. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of lowdose paclitaxel and cisplatin in combination with splitcourse concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 2007;25:4800-5. https://doi.org/10.1200/JCO.2006.07.9194
  13. Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007;68:731-40. https://doi.org/10.1016/j.ijrobp.2006.12.055
  14. Biagioli MC, Harvey M, Roman E, et al. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:1067-73. https://doi.org/10.1016/j.ijrobp.2007.04.057
  15. Den RB, Doemer A, Kubicek G, et al. Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensity-modulated radiotherapy: a prospective study. Int J Radiat Oncol Biol Phys 2010;76:1353-9. https://doi.org/10.1016/j.ijrobp.2009.03.059
  16. Wang J, Bai S, Chen N, et al. The clinical feasibility and effect of online cone beam computer tomography-guided intensity modulated radiotherapy for nasopharyngeal cancer. Radiother OncoI2009;90:221-7. https://doi.org/10.1016/j.radonc.2008.08.017
  17. Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA. Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;80:669-76. https://doi.org/10.1016/j.ijrobp.2010.02.023
  18. McDonald MW, Lawson J, Garg MK, et al. ACR Appropriateness Criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011;80:1292-8. https://doi.org/10.1016/j.ijrobp.2011.02.014
  19. Langlois D, Eschwege F, Kramar A, Richard JM. Reirradiation of head and neck cancers: presentation of 35 cases treated at the Gustave Roussy Institute. Radiother Oncol 1985;3:27-33. https://doi.org/10.1016/S0167-8140(85)80006-2
  20. Popovtzer A, Gluck I, Chepeha DB, et al. The pattern of failure after reirradiation of recurrent squamous cell head and neck cancer: implications for defining the targets. Int J Radiat Oncol Biol Phys 2009;74:1342-7. https://doi.org/10.1016/j.ijrobp.2008.10.042
  21. Sulman EP, Schwartz DL, Le n et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009;73:399-409. https://doi.org/10.1016/j.ijrobp.2008.04.021
  22. Stevens KR Jr, Britsch A, Moss WT. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1994;29:687-98. https://doi.org/10.1016/0360-3016(94)90555-X
  23. Pomp J, Levendag PC, van Putten WL. Reirradiation of recurrent tumors in the head and neck. Am J Clin Oncol 1988;11:543-9. https://doi.org/10.1097/00000421-198810000-00007
  24. Duprez F, Madani I, Bonte K, et al. Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol 2009;93:563-9. https://doi.org/10.1016/j.radonc.2009.10.012
  25. Rwigema JC, Heron DE, Ferris RL, et al. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol 2011 ;34:372-9. https://doi.org/10.1097/COC.0b013e3181e84dc0
  26. Cengiz M, Ozyigit G, Yazici G, et al. Salvage reirradiaton with stereotactic body radiotherapy for locally recurrent head-andneck tumors. Int J Radiat Oncol Biol Phys 2011;81:104-9. https://doi.org/10.1016/j.ijrobp.2010.04.027
  27. Balermpas P, Hambek M, Seitz 0, Rodel C, Weiss C. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol 2009;185:775-81. https://doi.org/10.1007/s00066-009-2092-7
  28. Zwicker F, Roeder F, Thieke C, et al. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 2011;187:32-8. https://doi.org/10.1007/s00066-010-2149-7
  29. Kao J, Genden EM, Chen CT, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer 2011;117:3173-81 . https://doi.org/10.1002/cncr.25786
  30. Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63:1400-12. https://doi.org/10.1016/j.ijrobp.2005.05.007

피인용 문헌

  1. Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis vol.10, pp.None, 2015, https://doi.org/10.1186/s13014-014-0320-5
  2. Tumor Regression Patterns Based on Follow-up Duration in Patients With Head and Neck Squamous Cell Carcinoma Treated With Radiotherapy or Chemoradiotherapy vol.8, pp.4, 2013, https://doi.org/10.3342/ceo.2015.8.4.416
  3. Image-guided radiation therapy (IGRT): practical recommendations of Italian Association of Radiation Oncology (AIRO) vol.121, pp.12, 2013, https://doi.org/10.1007/s11547-016-0674-x
  4. Re-irradiation for head and neck squamous cell carcinoma vol.29, pp.1, 2013, https://doi.org/10.1016/j.jnci.2016.07.002
  5. Patterns of local-regional recurrence after conformal and intensity-modulated radiotherapy for head and neck cancer vol.12, pp.None, 2017, https://doi.org/10.1186/s13014-017-0829-5
  6. A seven-gene signature to predict the prognosis of oral squamous cell carcinoma vol.40, pp.22, 2013, https://doi.org/10.1038/s41388-021-01806-5